The Filing Desk

CareDx

CDNA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CDNA · Last close · November 13, 2026
$77.88
Value CareDx yourself

CareDx's revenue rose 13.8% to $380 million in fiscal 2025. Its operating margin was −8.1%, down from 12.2% a year earlier. It paid out $88 million in dividends and buybacks. The diluted share count fell 5.9%.

CAREDX, INC. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001217234-26-000018 Updated
Revenue
$380M
13.8%
Operating margin
−8.1%
20.3 pts
Net income
−$21M
$52M a year earlier
Free cash flow
—
 
Return on capital
−20.0%
76.4 pts
Market cap
$4.3B
Nov 13 close
P/E
32.6x
On $2.39 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What CareDx does

CareDx makes tests and services for people who have had, or are waiting for, a heart, kidney or lung transplant. Its main products are blood tests that look for signs that the body may be rejecting the new organ without the need for a biopsy. They include AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare and AlloSure Lung. It also sells laboratory products, digital health tools and patient support services.

CareDx earns most of its revenue by running these tests in its own laboratories and billing for them. It says a substantial portion of revenue comes from Medicare. It reports a single segment. Substantially all of its revenue comes from the United States and Europe, and its operations are mainly in the United States and Sweden.

The company is based in Brisbane, California, with other main operations in Omaha, Nebraska and Stockholm, Sweden. It says it has a history of losses and expects more net losses for the next several years.

Its biggest risks, as it describes them

  • A substantial share of its revenue comes from Medicare, so lower reimbursement would hurt it badly.
  • Its results depend largely on sales of a handful of transplant tests.
  • Insurers may drop or limit coverage of its tests, or pay too little for them.
  • It has a history of losses and expects more net losses for the next several years.
  • Clinicians and medical centers may not adopt its tests, and rivals may keep pace with new technology.
From CareDx's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

CareDx lost money in fiscal 2025: a net loss of $21 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments348293235261177
Debt incl. finance leases00000
Net debt (negative means net cash)−348−293−235−261−177
Net debt to EBITDA———−4.7x—
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−29,726.0x−9,653.9x———
Current ratio5.6x5.1x4.0x3.9x2.9x
Quick ratio5.4x4.8x3.8x3.7x2.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project CareDx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought CareDx shares on the open market, and 7 insiders sold $13.6 million, $10.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 10, 2026Jeffrey Adam NovackSecretary and General CounselSold plan4,096$81.13$332,291Form 4
Aug 5, 2026George BickerstaffDirectorSold20,000$46.29$925,800Form 4
Aug 5, 2026Jeffrey Adam NovackSecretary and General CounselSold plan2,688$46.26$124,351Form 4
Aug 4, 2026Michael GoldbergDirectorSold44,700$47.06$2.1 millionForm 4
Aug 4, 2026Christine CournoyerDirectorSold plan16,000$46.94$751,040Form 4
Jul 16, 2026John Walter Hanna JRPresident and CEO, DirectorSold plan118,000$37.78$4.5 millionForm 4
Jul 16, 2026Hannah ValantineDirectorSold plan28,779$36.14$1.0 millionForm 4
Jun 29, 2026John Walter Hanna JRPresident and CEO, DirectorSold plan39,900$29.24$1.2 millionForm 4
Jun 26, 2026John Walter Hanna JRPresident and CEO, DirectorSold plan100$29.00$2,900Form 4
Jun 15, 2026John Walter Hanna JRPresident and CEO, DirectorSold plan17,683$24.03$424,922Form 4
Jun 15, 2026Hannah ValantineDirectorSold plan12,103$23.11$279,700Form 4
Jun 11, 2026John Walter Hanna JRPresident and CEO, DirectorSold plan21,998$24.02$528,392Form 4
The latest 12 of 22 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 84 of 84 of 8
Rule of 40———
Altman Z''−3.023.43−0.76
Accruals ratio−34.0%3.0%−14.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailPass
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score1 of 84 of 84 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put CareDx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CareDxFY2513.8%−8.1%—−20.0%—4
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4Compare
GeneDxFY2540.0%−3.1%3.3%−5.3%—6Compare
Starling OncologyFY2527.8%−7.2%−5.5%−75.7%—3Compare
VeracyteFY2516.0%11.2%24.5%6.1%−4.6x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue414877127192296322280334380
Revenue growth44.4%18.9%58.5%66.0%51.2%54.2%8.6%−12.9%19.1%13.8%
Gross profit30274482——————
Research and development12121431497690827271
Operating income−37−20−16−24−22−30−77−20341−31
Net income−40−56−47−22−19−31−77−19052−21
Diluted EPS (US$)−2.39−2.38−1.31−0.52−0.40−0.59−1.44−3.540.93−0.40
Diluted shares (millions)16233642465253545753
Cash flow
Cash from operations−16−14−4−333−19−25−183842
Capital expenditure002———————
Free cash flow−17−14−6———————
Dividends paid0000000000
Share buybacks000000128088
Acquisitions2161180151700
Stock-based compensation22722233647496635
Balance sheet at fiscal year end
Cash and short-term investments17176538225348293235261177
Debt incl. finance leases243400000000
Total assets7784131152368567543467491413
Total liabilities5790355391101112206113110
Shareholders' equity20−69699278466431261378303
Margins and ratios
Gross margin74.8%55.8%56.9%64.2%——————
Operating margin−91.9%−42.0%−20.4%−19.3%−11.7%−10.0%−24.0%−72.5%12.2%−8.1%
Net margin−97.1%−114.8%−61.1%−17.3%−9.7%−10.3%−23.8%−67.9%15.7%−5.6%
Free cash flow margin−42.0%−30.0%−7.9%———————
Rule of 40 (growth + FCF margin)2.4%−11.1%50.6%———————
Return on capital−141.1%−85.2%−57.9%−42.1%−31.3%−27.6%−47.8%−196.2%56.4%−20.0%
Return on equity−161.2%−831.1%−104.1%−22.5%−9.9%−8.2%−17.1%−55.0%16.4%−6.3%
Return on assets−59.6%−69.2%−43.6%−15.6%−7.2%−6.6%−13.8%−37.7%11.0%−4.7%
Net debt to EBITDA————————−4.7x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: CareDx's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with CareDx.